What is the Natural Capsules PE ratio today?
Natural Capsules' PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit attributable to shareholders over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹21.5 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹144 crore at ₹137.93 a share.
What is the Natural Capsules PB ratio (price to book value)?
Natural Capsules' price-to-book (PB) ratio is 0.65 at the 29 October 2026 close: a market capitalisation of ₹144 crore divided by shareholders' equity (book value) of ₹222 crore on 31 March 2026. That is a book value of ₹212.88 per share against a share price of ₹137.93.
What is the Natural Capsules book value per share?
Natural Capsules' book value per share was ₹212.88 on 31 March 2026: shareholders' equity of ₹222 crore divided by the 1.04 crore shares in issue, down 5.5% from ₹225.25 a year earlier. The share price at the 29 October 2026 close was ₹137.93.
What is the Natural Capsules market cap?
Natural Capsules' market capitalisation was ₹144 crore at the 29 October 2026 close: 1.04 crore shares at ₹137.93 each.
Is Natural Capsules debt free?
No. Natural Capsules had borrowings of ₹114 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.49. Its cash and current investments were ₹4.8 crore, so its net debt was ₹110 crore.
What is the Natural Capsules EPS?
Natural Capsules' basic earnings per share (EPS) were −₹23.84 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to −₹24.01.
What is the Natural Capsules debt to equity ratio?
Natural Capsules' debt-to-equity ratio was 0.49 on 31 March 2026: borrowings of ₹114 crore against total equity of ₹235 crore. A year earlier, on 31 March 2025, it was 0.40.
What is the Natural Capsules net worth?
Natural Capsules' net worth — shareholders' equity in its consolidated balance sheet — was ₹222 crore on 31 March 2026, down 4.9% from ₹233 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹144 crore at the 29 October 2026 close.
What is the Natural Capsules free cash flow?
In FY26, Natural Capsules generated ₹10.9 crore of cash from operations and spent ₹11.5 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹61 lakh. In FY25 it was −₹17.9 crore.
What is the Natural Capsules ROE and ROCE?
In FY26, Natural Capsules' return on equity (ROE) was −7.5% and its return on capital employed (ROCE) was −6.1%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
How does Natural Capsules compare with its peers?
On FY26 consolidated figures, against Nectar Lifesciences, Aarey Drugs & Pharmaceuticals and Bal Pharma: Natural Capsules' return on equity of −7.5% is the third highest of the four (Nectar Lifesciences −38.1%, Aarey Drugs & Pharmaceuticals 2.8%, Bal Pharma 7.9%; peer average −9.2%).
Natural Capsules vs Nectar Lifesciences: how do they compare?
In FY26, Natural Capsules earned net profit attributable to shareholders of ₹17.1 crore on revenue of ₹187 crore, against ₹293 crore on ₹0 lakh for Nectar Lifesciences. At the 29 October 2026 close, Natural Capsules' market capitalisation was ₹144 crore against ₹201 crore for Nectar Lifesciences.
What is the Natural Capsules promoter holding?
Promoters held 50.92% of Natural Capsules on 30 September 2026, unchanged from the previous quarter and down 0.34 percentage points from 51.26% a year earlier, according to the shareholding pattern filed with NSE.
What is the Natural Capsules revenue and profit in FY26?
In FY26 (April 2025–March 2026), Natural Capsules' consolidated net loss was ₹17.1 crore, against a profit of ₹62 lakh in FY25, on revenue from operations of ₹187 crore (up 10.6%).
When are the Natural Capsules next results?
Natural Capsules has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
What is the Natural Capsules shareholding pattern?
On 30 September 2026, Natural Capsules' shares were held by promoters 50.92%, foreign portfolio investors (FII/FPI) 0.08% and retail and other non-institutional investors 49.00%. Over the year, FII holding was up 0.08 percentage points from 0.00%.
What are the Natural Capsules latest quarterly results?
Natural Capsules' latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net loss ₹4 crore, narrower than the loss of ₹5.6 crore in Q1 FY26; revenue from operations ₹48.7 crore, up 7.8% year on year.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
